The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Amer ZeidanDuring the 63rd ASH Annual Meeting and Exposition, the MDS Hub was pleased to speak to Amer Zeidan, Yale School of Medicine, New Haven, US. We asked, What new developments are there in the treatment of relapsed or refractory myelodysplastic syndromes (MDS)?
What new developments are there in the treatment of relapsed or refractory MDS?
In this video, Zeidan discusses the treatment options for patients with MDS in the relapsed/refractory setting. In particular, he comments on the use of venetoclax, and hypomethylating agents such as azacitidine.